Tompkins Financial’s NovoCure NVCR Stock Holding History

Tompkins Financial’s Portfolio NVCR Stock Details NVCR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$758	Hold	50	–	–	﹤0.01%	538
2026 Q1	$545	Hold	50	–	–	﹤0.01%	548
2025 Q4	$647	Hold	50	–	–	﹤0.01%	614
2025 Q3	$646	Hold	50	–	–	﹤0.01%	530
2025 Q2	$890	Hold	50	–	–	﹤0.01%	524
2025 Q1	$891	Sell	50 -50	-50%	-$1.14K	﹤0.01%	539
2024 Q4	$2.98K	Hold	100	–	–	﹤0.01%	482
2024 Q3	$1.56K	Hold	100	–	–	﹤0.01%	541
2024 Q2	$1.71K	Hold	100	–	–	﹤0.01%	548
2024 Q1	$1.56K	Hold	100	–	–	﹤0.01%	583
2023 Q4	$1.49K	Hold	100	–	–	﹤0.01%	601
2023 Q3	$1.61K	Hold	100	–	–	﹤0.01%	544
2023 Q2	$4.15K	Hold	100	–	–	﹤0.01%	526
2023 Q1	$6.01K	Hold	100	–	–	﹤0.01%	522
2022 Q4	$7K	Hold	100	–	–	﹤0.01%	510
2022 Q3	$8K	Hold	100	–	–	﹤0.01%	496
2022 Q2	$7K	Hold	100	–	–	﹤0.01%	497
2022 Q1	$8K	Buy	+100	New	+$7.37K	﹤0.01%	505

Other funds holding NVCR

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

SCM

Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return

QCM

Quantinno Capital Management New York $83.3B AUM 37.97% 1-Year Est. Return

Tompkins Financial's NVCR Position: Q2 2026 in Review

Tompkins Financial held its NovoCure (NVCR) position steady in Q2 2026 at 50 shares worth $758. The position accounts for ﹤0.01% of the portfolio, ranked #538.

Tompkins Financial first reported a position in NVCR in Q1 2022 and has held it in 18 quarters since. The position peaked at $8K in Q3 2022. 216 funds tracked by Wall St. Rank hold NVCR as of Q2 2026.

Tompkins Financial held 50 shares of NovoCure worth $758 as of Q2 2026.
Tompkins Financial left its NovoCure share count unchanged in Q2 2026.
NovoCure made up ﹤0.01% of Tompkins Financial's portfolio in Q2 2026, its #538 holding.
Tompkins Financial first reported a position in NovoCure in Q1 2022 and has held it in 18 quarters since.
Tompkins Financial's NovoCure position peaked at $8K in Q3 2022.
216 funds tracked by Wall St. Rank held NovoCure as of Q2 2026.

Based on Tompkins Financial's 13F filing for Q2 2026, filed 15 Jul 2026.